Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis
To evaluate the efficacy and safety of pimecrolimus cream 1% in its registered indication (treatment of patients > 3 months of age with mild to moderate atopic dermatitis)
This study is not enrolling patients in the United States.
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
- Investigator Global Assessment (IGA) score for the whole body and for the face only.
- Pruritus (itch) severity assessments, and patient's self-assessment of disease control at the start of study and on day 7, 30 and 90 after treatment initiation.
- Safety assessed by adverse events.
|Study Start Date:||December 2004|
|Study Completion Date:||December 2005|
Drug: Pimecrolimus Cream 1%
|This study is not being conducted in the United States|
|Investigative Site, Philippines|
|Study Chair:||Novartis Healthcare Philippines||Novartis Pharmaceuticals|